Get research and free financial education.
Free financial education in line with Federal Financial Education Initiative.
Trending growth stocks for April 2026 are highlighted by strong expansion in AI infrastructure and weight-loss pharmaceutical sectors.
The following metrics are based on the latest available data as of April 6, 2026.
Nvidia (NVDA) continues to lead the AI hardware sector with a robust 62.5% year-over-year revenue growth. The company maintains exceptional profitability, reporting a 58.1% operating margin and a 56.5% net profit margin. In terms of valuation, it carries a forward price-to-earnings ratio of 54.0 and a price-to-sales ratio exceeding 25.0. Currently, the stock is trading 19.6% below its 52-week high of $212.19, indicating its potential room for recovery.
Palantir (PLTR) is experiencing significant momentum with a 62.8% revenue growth rate, largely driven by its expansion into the U.S. commercial market. It shows a healthy 33.3% operating margin and a 28.1% net profit margin. However, its valuation remains high with a forward P/E of 259.2 and a P/S ratio over 20.0. The stock has a substantial 39.8% gap to its one-year high of $207.52, representing the highest potential increase among this group to reach previous peaks.
Broadcom (AVGO) remains a steady grower in the semiconductor space with 29.0% revenue growth and an operating margin of 39.0%. Its net profit margin is approximately 25.0%, supported by a forward P/E of 27.7 and a P/S ratio above 12.0. The stock is currently positioned 31.8% below its 52-week high of $414.61, offering a significant margin for potential upside as it looks to reclaim its yearly high.
Micron (MU) is seeing a sharp 56.3% increase in revenue due to the high demand for memory in AI applications. Its operating margin stands at 20.7% with a net profit margin of 15.4%. Micron offers a lower valuation profile compared to its peers, with a forward P/E of 6.3 and a P/S of 2.5+. It is currently trading 24.8% below its one-year high of $471.34.
Eli Lilly (LLY) dominates the pharmaceutical growth landscape with 43.0% revenue growth fueled by its GLP-1 drug portfolio. The company manages an operating margin of roughly 35.0% and a net profit margin of 28.0%. With a forward P/E of 43.8 and a P/S of 15.0, it is currently 22.3% below its 52-week high of $1,133.95.
All content is for informational purposes only, not advice.
